• GSK 2837808A in LDHA and CRC Metabolism Research

  2026-10-05

  GSK 2837808A is a supplier-described LDHA-focused small molecule relevant to cancer metabolism research, while recent colorectal cancer evidence centers on the NAT1–ENO1–lactate–PD-L1 pathway. This overview compares the compound’s reported biochemical and pharmacokinetic profile with findings from a 2026 MedComm study, emphasizing that LDHA inhibition has not yet been directly validated as a way to reproduce the study’s immune effects. The evidence remains preclinical, model-dependent, and insufficient to support clinical or therapeutic conclusions.

• DiI (DiIC18(3)) Product Overview

  2026-10-05

  DiI (DiIC18(3)), SKU B8804, is an APExBIO-listed lipophilic orange fluorescent membrane probe. The available information supports product identity and conceptual scope only; no matched paper evidence was supplied to establish performance, mechanism, or application-specific outcomes.

• Anlotinib and Angiogenesis: Evidence from a 2018 Study

  2026-10-04

  The 2018 Gene study identified anlotinib as a multi-target tyrosine kinase inhibitor that suppresses angiogenic signaling through VEGFR2, PDGFRβ, FGFR1, and downstream ERK. By combining endothelial-cell, ex vivo tissue, and CAM models, the work linked receptor-level inhibition with reduced migration, tube formation, and vascular sprouting, while leaving clinical translation to future research.

• From Antibody Maps to Translational Readouts

  2026-10-03

  Orthopoxvirus antibody discovery increasingly depends on connecting epitope-level mechanism with reproducible human IgG measurement. This thought-leadership article examines how the Cy3 Goat Anti-Human IgG (H+L) Antibody can support research readouts while distinguishing product attributes from evidence generated in preclinical antibody studies.

• Pheromone Signaling and Neurodegeneration in C. elegans

  2026-10-02

  Peng et al. show that pheromone exposure during the L1 stage can reprogram neuronal development and accelerate neurodegeneration in adult C. elegans. The study identifies a synergistic ASK–ASI–AIA circuit that connects environmental chemical sensing with insulin-like signaling and reduced neuronal autophagy.

• Exemestane Workflows for Aromatase Research

  2026-10-01

  Build reproducible aromatase assays with Exemestane, from solvent preparation and time-dependent inhibition studies to breast cancer research models. Practical controls, concentration guidance, and troubleshooting help distinguish true estrogen biosynthesis inhibition from matrix, precipitation, or readout artifacts.

• Gemini QACs: Broad-Spectrum Biocidal Design

  2026-10-01

  A 2024 Bioorganic Chemistry study synthesized 16 octenidine-derived gemini quaternary ammonium compounds and identified leads with improved antibacterial, antifungal, and virucidal profiles. Its results show why antimicrobial potency, biofilm activity, cytotoxicity, solubility, and membrane-permeation predictions should be evaluated together rather than as isolated endpoints.

• p-Cresyl sulfate: Reliable Cell Assay Workflows

  2026-09-30

  This scenario-based guide explains how p-Cresyl sulfate, SKU A8895, can improve interpretation of viability, proliferation, wound-healing, and apoptosis assays. It covers preparation, albumin context, controls, vendor selection, and the limits of translating endothelial findings to hepatobiliary models.

• Ibrexafungerp Activity Against Resistant Candida auris

  2026-09-30

  Wiederhold and colleagues evaluated Ibrexafungerp, also known as MK 3118, against fluconazole-resistant Candida auris using broth microdilution and a neutropenic mouse model of invasive candidiasis. The study found consistent in vitro activity and meaningful reductions in mortality and kidney fungal burden when treatment began 24 hours after infection, supporting further investigation of oral glucan synthase inhibition for resistant C. auris.

• CB-5083: Practical p97 Inhibitor Workflows

  2026-09-29

  This scenario-driven guide explains how CB-5083, SKU B6032, can support reproducible cell viability, proliferation, and cytotoxicity studies through controlled dosing, solvent handling, and orthogonal endpoint selection. It connects biochemical p97 inhibition with protein homeostasis disruption while clearly separating established evidence from practical workflow recommendations.

• Mitoxantrone Targets the ERα DBD–LBD Interface

  2026-09-29

  Wang and colleagues identify mitoxantrone as a ligand for a previously underexplored interface between the estrogen receptor α DNA-binding and ligand-binding domains. Their data show that this interaction redirects ERα, promotes proteasomal degradation, and suppresses therapy-resistant ER signaling through a mechanism distinct from conventional hormone-pocket antagonism.

• Sulforaphane, Oxidative Stress, and NLRP3 in Colitis

  2026-09-28

  A 2024 mouse study shows that Sulforaphane reduces DSS-induced colitis alongside lower reactive oxygen species and suppressed NLRP3 inflammasome signaling. The work links redox imbalance to NLRP3–ASC–caspase-1 activation and provides a practical framework for studying inflammasome-driven intestinal inflammation.

• Sunitinib Workflows for RCC Resistance Research

  2026-09-28

  Turn Sunitinib’s multi-target RTK activity into a reproducible workflow for renal cell carcinoma, angiogenesis, and treatment-resistance studies. A recent TRIB3 study adds a ferroptosis-focused way to test sensitization—while practical controls help separate target inhibition from cell-death effects.

• Gepotidacin Mechanism at Staphylococcus aureus Gyrase

  2026-09-27

  This study shows that gepotidacin inhibits Staphylococcus aureus gyrase through a cleavage-complex mechanism distinct from the double-strand breaks associated with fluoroquinolones. Biochemical assays and two crystal structures link potent inhibition to single-strand DNA cleavage and reveal how one gepotidacin molecule occupies a pocket between the enzyme’s GyrA subunits.

• GSK 2837808A for LDHA and Lactate Research

  2026-09-26

  Use GSK 2837808A to test whether LDHA activity contributes to lactate production, glucose use, and cancer-cell metabolic phenotypes. This workflow distinguishes the compound’s established LDHA evidence from hypothesis-generating applications to the NAT1–ENO1–lactate pathway in colorectal cancer.

8649 records 1/577 page Next 12345 下5页 Last page